ACRIA Studies in Progress

• Tipranavir Open Label Safety Study
• UK-427,857 for Drug-Resistant HIV
• The Effect of Reyataz on Cholesterol Levels
• Reyataz Compared to Kaletra
• One-Day Study of Reyataz Resistance
• Phase I Study of a New GlaxoSmithKline NNRTI
• Standard of Care Treatment vs. ZEST Once-Daily Regimen

Tipranavir Open Label Safety Study

People whose virus has become resistant to approved HIV treatments or who are intolerant to them will take tipranavir with Norvir, along with other anti-HIV drugs, for an open period of time. Participants should be 13 years of age or older, have a viral load above 10,000 and a CD4 count below 100 to enroll in this program.

UK-427,857 for Drug-Resistant HIV

People who have taken anti-HIV drugs from three of the four classes of drugs will take either UK-427 (an experimental HIV attachment inhibitor) with an optimized regimen of anti-HIV drugs, or take a placebo (dummy pill) with the optimized regimen, for 11 months. Participants must be 16 or older and have a viral load of at least 5,000.

The Effect of Reyataz on Cholesterol Levels

People who have high cholesterol levels and a viral load below 50 while taking Kaletra will either switch to Reyataz or continue taking Kaletra. The study will last 12 months. Study participants will be reimbursed $25 for each visit.

Reyataz Compared to Kaletra

People whose viral load has risen to over 1,000 while taking an NNRTI as part of their first HAART regimen will switch to either Kaletra, or to Reyataz/Norvir. Everyone will also take Viread and either Videx EC or Zerit XR. The study will last for 22 months. Study participants will be reimbursed $25 for each visit.

One-Day Study of Reyataz Resistance

People whose viral load has risen to over 1,000 while taking Reyataz will have blood tests for resistance, CD4, and viral load. Study participants will be reimbursed $25.

Phase I Study of a New GlaxoSmithKline NNRTI

People who have become resistant to an NNRTI and who have a CD4 count over 200 and a viral load over 2,000 will take one of four doses of W695634G alone, or take placebo pills, for 7 days. Those who complete the study will be reimbursed $590.

For the above trials, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at ext. 124.

Standard of Care Treatment vs. ZEST Once-Daily Regimen

(Closed to Enrollment) This trial is studying whether people on their first HAART regimen who take their drugs two or more times a day can switch to a once-daily regimen. People in the trial either remain on their current medications, or switch to Zerit XR, Epivir and Sustiva (ZEST) taken once daily.